Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein naked cuticle homolog 1 (NKD1) is a crucial negative feedback regulator of the Wnt signaling pathway, which plays a fundamental role in embryonic development and tissue regeneration [1, 2, 8]. NKD1 acts by binding to Dishevelled (Dvl) and beta-catenin, thereby preventing the nuclear translocation of beta-catenin and inhibiting the transcription of Wnt-responsive genes [5, 12, 17]. Although it typically functions as a tumor suppressor, its role in oncology is complex and tissue-specific [9, 11]. In glioblastoma and hepatocellular carcinoma, reduced NKD1 levels are linked to poor clinical outcomes, whereas in colorectal cancer, high NKD1 expression may actually promote tumor growth by stabilizing the MYC protein [6, 9, 11]. As a result, NKD1 is an emerging target for therapeutic intervention and a potential biomarker for patient stratification in Wnt-driven diseases [13, 15].
Antagonism of the Wnt signaling pathway by binding to Dishevelled (Dvl) and beta-catenin, thereby preventing the nuclear translocation of beta-catenin and inhibiting Wnt-mediated gene transcription [1, 5, 12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein naked cuticle homolog 1 (NKD1) (NKD1).